



CANCER PREVENTION & RESEARCH  
INSTITUTE OF TEXAS

**Oversight Committee Meeting**  
**August 24, 2018**

NOTE: Unless the information is confidential, the reports and presentations referenced in the minutes are available at [http://www.cprit.state.tx.us/cprit-media/oc\\_packet\\_08-24-2018.pdf](http://www.cprit.state.tx.us/cprit-media/oc_packet_08-24-2018.pdf)  
Information regarding the recommended awards is available at [http://www.cprit.state.tx.us/cprit-media/proposed\\_grant\\_awards\\_book\\_08242018.pdf](http://www.cprit.state.tx.us/cprit-media/proposed_grant_awards_book_08242018.pdf)

**Call to Order – Agenda Item 1**

A quorum being present, Presiding Officer Will Montgomery called the Oversight Committee to order at 10:05 a.m.

**Roll Call/Excused Absences – Agenda Item 2**

Committee Members Present

Angelos Angelou  
Bill Rice, M.D.  
Donald (Dee) Margo  
Will Montgomery  
Mahendra Patel, M.D.

Committee Members Absent

Craig Rosenfeld, M.D.

**MOTION:**

On a motion by Mr. Margo and seconded by Dr. Rice, the Oversight Committee unanimously voted to approve the excused absence of Dr. Rosenfeld.

**Adoption of Minutes from the May 16, 2018, Meeting – Agenda Item 3 – Tab 1**

**MOTION:**

On a motion by Mr. Angelou and seconded by Dr. Rice, the Oversight Committee unanimously voted to approve the minutes of the Oversight Committee meeting of May 16, 2018, as presented.

**Public Comment – Agenda Item 4**

There were no requests to provide public comment.

**Grantee Presentation – Agenda Item 5 – Tab 2**

Dr. Garcia introduced Dr. Barbara Turner, Professor of Medicine at UT Health San Antonio and the Founding Director of the Center for Research to Advance Community Health.

Dr. Turner reported on the successful CPRIT-funded Screen, Treat, or Prevent HCC (hepatocellular carcinoma) project, PP150079, and PP180063, the dissemination award for this model.

In response to an Oversight Committee member's question about individuals most at risk for HCC, Dr. Turner explained that those with chronic Hepatitis C are at highest risk. Another member asked about the project's use of telemedicine. Dr. Turner replied that the patient's primary care doctor and the specialist develop a treatment plan together using telemedicine. A member asked how many individuals that program has treated for Hepatitis C infections under this program. Dr. Turner reported that the program treated 84 uninsured patients, with 72 cured. At Parkland Hospital, one-third of the 400-500 patients in that safety-net healthcare system were cured.

### **Chief Executive Officer Report – Agenda Item 6 – Tab 3**

Presiding Officer Montgomery recognized Mr. Roberts for the CEO report.

Mr. Roberts introduced Melanie Cleveland as CPRIT's new Executive Assistant.

Addressing the FY 2018 budget, Mr. Roberts explained that if the Oversight Committee approved all the proposed awards, approximately \$3.1 million in agency funds would remain.

Mr. Roberts reported that the American Cancer Society Cancer Action Network held two events in July and August in Austin and Fort Worth.

Mr. Roberts noted that the Oversight Committee will consider the FY 2020 program priorities at its November meeting. He expects that many of the priorities would remain the same as FY 2019 priorities.

Mr. Roberts finished his report with an update about the next CPRIT Conference, which will be held in 2020. He explained that holding the conference in 2020 aligns the timing with the legislative cycle, increases venue choices, and allows staff to repurpose the existing registration system.

There were no questions for Mr. Roberts.

Presiding Officer Montgomery congratulated Mr. Roberts for receiving the "Administrator of the Year" award from the Texas State Agency Business Administrator's Association (TSABAA). The award recognizes state employees who have demonstrated outstanding leadership skills and who have made significant contributions to state agency business administration. Presiding Officer Montgomery thanked Mr. Roberts for his efforts on behalf of CPRIT and his 40-year career dedicated to Texas.

### **Chief Compliance Officer Report – Agenda Item 7 – Tab 4**

Stephen Nance, CPRIT's Compliance Program Manager, presented the Compliance Report in Chief Compliance Officer Vince Burgess's absence. CPRIT included the report in the meeting agenda packet. Mr. Nance informed the Oversight Committee that CPRIT has fully implemented the revised process for submitting the Single Audit Determination forms. Grantees will complete and submit one form to CPRIT on an annual basis.

Mr. Nance reported that CPRIT completed the Annual Grantee Risk Assessment for FY 2019 and explained that the assessment was discussed with the Audit Subcommittee.

The Oversight Committee had no questions for Mr. Nance.

**Chief Scientific Officer Report – Agenda Item 8 – Tab 5**

Presiding Officer Montgomery recognized CPRIT Chief Scientific Officer James Willson to present the academic research program update and the award slates recommended by the CPRIT Scientific Review Council (SRC) and the Program Integration Committee (PIC).

Dr. Willson referred the members to the information on the status of FY 2019 Academic Research RFAs presented in the meeting books on pages 5-3 to 5-4. He noted the recent announcement of two new RFAs, the revised Early Translational Research Award and the Collaborative Action Program to Reduce Liver Cancer Mortality in Texas to reverse the state’s liver cancer trajectory.

Dr. Willson presented 51 grant awards from six grant mechanisms recommended by the SRC and the PIC totaling \$112,156,309. He summarized each of the award slates. Dr. Willson noted that because the SRC’s recommendations exceed the funds available to fund Academic Research Program awards for the final quarter of 2018, the PIC recommended that the Core Facility Support awards be reduced by 8% of the SRC’s recommended levels.

Grant Mechanism	SRC Recommendations		PIC Recommendations	
	Awards	Funding	Awards	Funding
High Impact/High Risk Research Awards	25	\$4,998,787	25	\$4,998,787
Core Facility Support Awards	10	\$49,147,362	10	\$45,215,573
Multi-Investigator Research Awards	5	\$29,941,949	5	\$29,941,949
Recruitment of Established Investigators	2	\$12,000,000	2	\$12,000,000
Recruitment of Rising Stars	1	\$4,000,000	1	\$4,000,000
Recruitment of First-Time, Tenure-Track Faculty Members	8	\$16,000,000	8	\$16,000,000
<b>Total</b>	<b>51</b>	<b>\$116,088,098</b>	<b>51</b>	<b>\$112,156,309</b>

Compliance Certification (Academic Research, Product Development, and Prevention Awards)

Mr. Nance presented Mr. Burgess’ certification of the review process for the proposed 51 academic research awards, 3 product development research awards, and 10 prevention awards recommended to the Oversight Committee for consideration. (Mr. Burgess’s certification is included in the proposed grant awards packet at pages 187-196.)

Conflict of Interest Notification

Presiding Officer Montgomery noted that Mr. Angelou reported a conflict of interest with grant applications RP180690, RP180880, and RR180042 submitted by The University of Texas at Austin.

Presiding Officer Montgomery suggested that, unless a member objected, the Oversight Committee consider all the academic research award recommendations together in one vote except for the proposed awards to The University of Texas at Austin, which the committee would vote on separately. No member objected.

### Academic Research Award Slate

ID	Award Mechanism	Meeting Overall Score	Application Title	PI	PI Organization	Recommended Budget
RP180684	CFSA	1.1	Integrated Single Cell Genomics Core Facility	Navin, Nicholas, Ph.D.	The University of Texas M. D. Anderson Cancer Center	\$5,323,453
RP180778	MIRA	1.3	Metabolic Enablers of Melanoma Progression	Morrison, Sean, Ph.D.	The University of Texas Southwestern Medical Center	\$5,998,327
RP180785	CFSA	1.5	CARMIT (Children’s Access to Regenerative Medicine in Texas)	Gee, Adrian, Ph.D.	Baylor College of Medicine	\$5,767,448*
RP180804	CFSA	1.9	Protein Array and Analysis Core (PAAC)	Bedford, Mark, Ph.D.	The University of Texas M. D. Anderson Cancer Center	\$2,819,682
RP180755	HIHRA	1.9	The Early-Life Exposome and Risk of Pediatric Acute Lymphoblastic Leukemia	Lupo, Philip Ph.D.	Baylor College of Medicine	\$199,140
RP180770	CFSA	1.9	Preclinical Radiation Core Facility (PCRCF)	Story, Michael, Ph.D.	The University of Texas Southwestern Medical Center	\$4,047,022
RP180700	HIHRA	2.0	Mechanisms of Drug Resistance in Lung Cancer	Alto, Neal Ph.D.	The University of Texas Southwestern Medical Center	\$200,000
RP180835	HIHRA	2.0	Targeted Proteolysis of Glucocorticoid Receptor as a Therapeutic Strategy in Antiandrogen Treatment-Resistant Prostate Cancer	Lissanu Deribe, Yonathan M.D., Ph.D.	The University of Texas M. D. Anderson Cancer Center	\$199,999
RP180805	CFSA	2.0	Pediatric Cancer Data Core	Xie, Yang, M.D., Ph.D.	The University of Texas Southwestern Medical Center	\$5,863,959***

RP180748	CFSA	2.1	GCC Center for Comprehensive PK/PD and Formulation	Liang, Dong Ph.D.	Texas Southern University	\$5,550,456
RP180694	HIHRRRA	2.2	TREX2 Inhibitors to Treat BCR-ABL- Cancers	Hasty, E. Paul DVM	The University of Texas Health Science Center at San Antonio	\$200,000
RP180769	HIHRRRA	2.2	A Novel Anti-BCR-ABL Approach for Leukemia Therapy	Rao, Hai Ph.D.	The University of Texas Health Science Center at San Antonio	\$200,000
RP180813	MIRA	2.2	BRCA Answers From Cancer Interactome Structures (BACIS)	Tainer, John, Ph.D.	The University of Texas M. D. Anderson Cancer Center	\$5,969,140
RP180672	CFSA	2.2	Advanced Multiparameter Cytometry and Cell Sorting Core	Beeton, Christine, Ph.D.	Baylor College of Medicine	\$5,628,254**
RP180712	MIRA	2.2	Rational Combination Treatment Options to Reverse Resistance in Hormone Receptor-Positive Breast Cancer Refractory to Standard Therapy	Hunt, Kelly, M.D.	The University of Texas M. D. Anderson Cancer Center	\$5,992,274
RP180819	CFSA	2.2	Pediatric Solid Tumors Comprehensive Data Resource Core	Gorlick, Richard, M.D.	The University of Texas M. D. Anderson Cancer Center	\$5,440,485***
RP180716	HIHRRRA	2.2	Noninvasive Diagnostic Imaging of Brain Cancer Using Hyperpolarized <sup>13</sup> C-Labeled L-Tryptophan and L-Methionine	Lumata, Lloyd, Ph.D.	The University of Texas at Dallas	\$200,000
RP180670	CFSA	2.3	Small Animal Imaging Core Facility for Cancer Research at UT Dallas	Hoyt, Kenneth, Ph.D.	The University of Texas at Dallas	\$3,892,336
RP180880	HIHRRRA	2.3	Targeting BRAF- and RAS-Mutant Cancers by Small Molecule-Induced Proteolysis of ERK1/2	Dalby, Kevin N, Ph.D.	The University of Texas at Austin	\$200,000
RP180734	CFSA	2.3	UTHealth Cancer Genomics Core (UTHealth CGC)	Zhao, Zhongming, Ph.D.	The University of Texas Health Science Center at Houston	\$4,814,267

RP180674	MIRA	2.4	Predictive Biomarkers and Novel Therapies for High-Risk Pediatric Liver Cancers	Lopez-Terrada, Dolores, M.D., Ph.D.	Baylor College of Medicine	\$5,982,208
RP180848	HIHRRRA	2.5	Autoimmune-Prone Mouse Models for Studying Immune-Related Adverse Events Associated With Cancer Immunotherapy	Yan, Nan Ph.D.	The University of Texas Southwestern Medical Center	\$200,000
RP180826	HIHRRRA	2.5	Integrative Analysis of Structural Variants in Cancer Genomes	Xu, Jian Ph.D.	The University of Texas Southwestern Medical Center	\$200,000
RP180690	HIHRRRA	2.6	Engineering Cancer Immunotherapeutics for Enhanced Activity in the Low pH Tumor Microenvironment	Maynard, Jennifer Ph.D.	The University of Texas at Austin	\$200,000
RP180812	HIHRRRA	2.6	Fluorescently Labeled Somatostatin Analogs for Image-Guided Surgery in Neuroendocrine Tumors	Azhdarinia, Ali Ph.D.	The University of Texas Health Science Center at Houston	\$200,000
RP180736	HIHRRRA	2.7	Nanoparticle-Mediated Hyperthermia to Improve Chemotherapeutic Efficacy in HIPEC	Holder, Ashley Ph.D.	The Methodist Hospital Research Institute	\$199,998
RP180751	HIHRRRA	2.8	Methods for Assessment and Quantification of Imperfect dsDNA Break Repair	Otwinowski, Zbyszek Ph.D.	The University of Texas Southwestern Medical Center	\$200,000
RP180801	HIHRRRA	2.8	Targeting the Menopause Transition to Decrease the Risk for Obesity-Associated Postmenopausal Breast Cancer	Giles, Erin D Ph.D.	Texas A&M University	\$200,000
RP180725	MIRA	2.8	Targeting Tumor Tissues Increases DNA Sensing to Bridge Innate and Adaptive Immunity	Fu, Yang-Xin, M.D., Ph.D.	The University of Texas Southwestern Medical Center	\$6,000,000

RP180863	HIHRRRA	2.9	Chemoprevention of Colon Cancer Progression in FAP Children	Hu, Ming Ph.D.	University of Houston	\$200,000
RP180771	HIHRRRA	2.9	Small Molecule for Selective Targeting of Epithelial-Mesenchymal Transition-Induced Cancer Stem Cells	Taube, Joe Ph.D.	Baylor University	\$199,951
RP180810	HIHRRRA	2.9	Controlling the Activity of Anticancer T Cells by Inducing Replicative Senescence	Mamonkin, Maksim Ph.D.	Baylor College of Medicine	\$200,000
RP180875	HIHRRRA	2.9	Cyanine-Conjugated Kinase Inhibitors (Cy-KIs) as Potential Glioblastoma Theranostics	Sitcheran, Raquel Ph.D.	Texas A&M University System Health Science Center	\$200,000
RP180882	HIHRRRA	3.0	Developing a Clinically Relevant Drug Testing Platform	Yun, Kyuson Ph.D.	The Methodist Hospital Research Institute	\$199,700
RP180846	HIHRRRA	3.0	Molecular Opening of the Blood-Brain Barrier by Molecular Hyperthermia	Qin, Zhenpeng Ph.D.	The University of Texas at Dallas	\$200,000
RP180827	HIHRRRA	3.1	Polymer Nanodiscs: Novel Lipoprotein-Mimicking Nanocarriers With High Stability and Long Circulation Time for Enhanced Anticancer Drug Delivery	Liang, Hongjie Ph.D.	Texas Tech University Health Sciences Center	\$200,000
RP180844	HIHRRRA	3.2	Regulating Androgen Receptor as a Corepressor by Neurofibromin (NF1)	Chang, Eric C. Ph.D.	Baylor College of Medicine	\$200,000
RP180873	HIHRRRA	3.2	Molecular Targeted Magnetic Resonance Reporter for Cancer Detection	Carson, Daniel Ph.D.	Rice University	\$200,000
RP180862	HIHRRRA	3.3	Microfluidic Cancer Assay for Liquid Biopsies and Early Detection	Pappas, Dimitri Ph.D.	Texas Tech University	\$199,999
RP180851	HIHRRRA	3.4	Targeting MYCN-Driven Metabolism in Neuroblastoma	Barbieri, Eveline M.D., Ph.D.	Baylor College of Medicine	\$200,000

\*RP180785 reflects the budget as reduced by the SRC. SRC recommended the removal of 2<sup>nd</sup> Prodigy Cell Processor  
 \*\*RP180672 reflects the recommended budget as reduced by the SRC. SRC recommended the elimination of salary support for Bioinformatician

\*\*\*RP180805 and RP180819 - The SRC notes that Core Facility Support Award applications from UT Southwestern (RP180805) and MD Anderson (RP180819) propose separate comprehensive data cores to support pediatric cancer research in Texas. The goals of the individual applications complement each other and together represent a unique opportunity to build a statewide resource that will accelerate pediatric cancer research in Texas. To realize the full potential of the CPRIT investment in these cores, the SRC recommended that prior to finalizing a funding plan for each core that the PIs and their respective institutions develop a plan that maximizes opportunities for the two cores to work together and to incorporate that plan into their core's goals and budget.

**Recruitment Slate**

App ID	Candidate	Mechanism	Organization	Budget	Overall Score
RR180061	Chao Cheng, Ph.D.	RRS	Baylor College of Medicine	\$4,000,000	1.0
RR180066	Xuebing Wu, Ph.D.	RFTFM	Baylor College of Medicine	\$2,000,000	1.2
RR180060	Yejing Ge, Ph.D.	RFTFM	The University of Texas M. D. Anderson Cancer Center	\$2,000,000	1.2
RR180072	Tao Wu, Ph.D.	RFTFM	Baylor College of Medicine	\$2,000,000	1.4
RR180032	Peng (George) Wang, Ph.D.	REI	Baylor College of Medicine	\$6,000,000	1.5
RR180051	Glen P. Liszczak, Ph.D.	RFTFM	The University of Texas Southwestern Medical Center	\$2,000,000	1.8
RR180050	Peter Ly, Ph.D.	RFTFM	The University of Texas Southwestern Medical Center	\$2,000,000	1.8
RR180056	Anke Henning, Ph.D.	REI	The University of Texas Southwestern Medical Center	\$6,000,000	2.0
RR180067	Fuguo Jiang, Ph.D.	RFTFM	The University of Texas M. D. Anderson Cancer Center	\$2,000,000	2.0
RR180042	Can Cenik, Ph.D.	RFTFM	The University of Texas at Austin	\$2,000,000	2.0
RR180071	Sung-Man (Kenneth) Chen, M.D.	RFTFM	The University of Texas Southwestern Medical Center	\$2,000,000	2.4

Responding to an Oversight Committee member's question about the Academic Research Program priorities represented in the six slates, Dr. Willson explained that the grant award recommendations

incorporated many of the program priorities. He referred the members to table 2 on page 13 of the Proposed Grant Awards book.

**MOTION:**

On a motion made by Dr. Rice and seconded by Mr. Margo, the Oversight Committee unanimously voted to approve the PIC's recommendations for The University of Texas at Austin grant applications RP180690, RP180880, and RR180042.

Presiding Officer Montgomery noted for the record that Mr. Angelou did not vote on these recommendations.

**MOTION:**

On a motion made by Mr. Angelou and seconded by Mr. Rice, the Oversight Committee unanimously voted to approve the PIC's recommendations for the remaining Academic Research and Recruitment Awards.

**MOTION:**

On a motion made by Dr. Rice and seconded by Mr. Angelou, the Oversight Committee unanimously voted to approve the delegation of contract negotiation authority to CPRIT's CEO and staff and authorized the CEO to sign the contracts on behalf of CPRIT.

**Chief Product Development Officer Report – Agenda Item 9 – Tab 6**

Presiding Officer Montgomery recognized Chief Product Development Research Officer Michael Lang to present the Product Development Review Council's (PDRC) and the PIC's recommendations for product development awards and to provide an update on the product development program.

Mr. Lang updated the Oversight Committee on the progress of the first funding cycle for FY 2019, referring members to his report in the meeting books. He noted that the 19.1 review cycle represents the first time that the Product Development program has offered the Seed Award funding mechanism. He reported that CPRIT received 27 applications for the new Seed Award.

Mr. Lang responded to an Oversight Committee member's question regarding whether CPRIT can accelerate the review process for the Seed Award in comparison to the review process for the other product development awards. Mr. Lang explained that although the Seed Award applications will include less information since the projects will be at an earlier development stage, the applications will undergo the same process and sequence for review as the other awards to comply with CPRIT policy and minimize budget impact.

Mr. Lang presented three product development awards recommended by the PDRC and the PIC totaling \$50,587,540. He explained that all the recommended applications address one or more of the Product Development Program priorities. Mr. Lang reported that Magnolia Neurosciences acquired Korysso Therapeutics and renamed it Magnolia Tejas. He also noted that the PDRC and PIC award recommendation for Korysso included several contract contingencies the company must resolve before CPRIT and the company can execute the award contract.

Application ID	Mech	Company Name	Project	Maximum Recommended Budget
DP180040	TXCO	Formation Biologics Corp.	Clinical Evaluation of AVID100, a Highly Potent Antibody-Drug Conjugate, Focusing on Cancer Indications With High Unmet Medical Need	\$18,850,000
DP180048	TXCO	Korysso Therapeutics, Inc.	Development of KOR-8287 for the Prevention of Chemotherapy-Induced Peripheral Neuropathy and Chemo Brain	\$19,953,624
DP180042	TXCO	CerRx, Inc.	Combination Drug Therapy for Cutaneous T-Cell Lymphoma	\$11,783,916

#### Compliance Certification

Presiding Officer Montgomery reminded members that Mr. Burgess previously certified compliance of the product development award process, as reported by Mr. Nance.

#### Conflict of Interest Notification

Presiding Officer Montgomery confirmed that no members reported a conflict of interest with any of the product development award recommendations.

#### **MOTION:**

On a motion made by Dr. Rice and seconded by Mr. Angelou, the Oversight Committee unanimously voted to approve the PIC's recommendation for the three product development research awards.

#### **MOTION:**

On a motion made by Mr. Angelou and seconded by Dr. Rice, the Oversight Committee unanimously voted to approve the delegation of contract negotiation authority to CPRIT's CEO and staff and authorized the CEO to sign the contracts on behalf of CPRIT.

#### **MOTION:**

On a motion made by Dr. Rice and seconded by Mr. Margo, the Oversight Committee unanimously voted to authorize CPRIT to disburse grant funds via advance payments to DP180040, DP180042, and DP180048 upon execution of the award contracts and the successful completion of tranches pursuant to the General Appropriations Act, Article IX, Section 4.03(a).

## Chief Prevention and Communications Officer Report – Agenda Item 10 – Tab 7

Presiding Officer Montgomery recognized Dr. Garcia to present the Prevention Review Council’s (PRC) and the PIC’s recommendations for prevention awards and to provide an update on the prevention program.

Dr. Garcia reported that CPRIT will post the 2018 Texas Cancer Plan on CPRIT’s website by the end of August and printed copies sent to the Oversight Committee in September.

Dr. Garcia presented ten projects, representing three grant mechanisms, recommended by the PRC and PIC, totaling \$14,322,379. The PIC agreed with the PRC’s recommendation to reduce the budgets of all recommended projects by 10.02% to assure that enough funds are available. She reported that all the recommended awards address one or more of the Prevention Program priorities.

App. ID	Mech	Application Title	PD	Organization	Score	Rank Order	Budget
PP180080	EBP	HPV Vaccination in a Pediatric Minority-Based Community Oncology Network	Grimes, Allison	The University of Texas Health Science Center at San Antonio	1.6	1	\$1,010,690
PP180091	EPS	STOP-HCC Expansion Grant	Jain, Mamta	The University of Texas Southwestern Medical Center	1.9	2	\$2,592,731
PP180026	EBP	Pasos Para Prevenir Cancer: Obesity-related Cancer Prevention in El Paso	Salinas, Jennifer J	Texas Tech University Health Sciences Center at El Paso	2.0	3	\$1,244,512
PP180086	EBP	Liver Cancer Prevention among those with Experiences of Homelessness	Schick, Vanessa R	The University of Texas Health Science Center at Houston	2.3	4	\$1,159,751
PP180082	EBP	West Texas HCV Screening and Linkage to Care Program	Gallegos, Patricia	Centro San Vicente	2.4	5	\$1,349,700
PP180018	EBP	BSPAN4: Optimizing Spatial Access to High-Quality Breast Screening & Patient Navigation for Rural Underserved Women across North Texas	Craddick Lee, Simon	The University of Texas Southwestern Medical Center	2.5	6	\$1,349,700

PP180077	TCL	Increasing Access to Smoking Cessation and Smoke Free Home Services for Low-Income Pregnant Women in Northeast Texas	Blalock, Janice A	The University of Texas M. D. Anderson Cancer Center	2.6	7	\$1,346,919
PP180092	TCL	Tobacco Services for Primary Care & Cancer Patients at UT Health San Antonio	Ramirez, Amelie G	The University of Texas Health Science Center at San Antonio	2.6	8	\$1,324,982
PP180012	EBP	Vaccinating medically underserved women against HPV	Berenson, Abbey B	The University of Texas Medical Branch at Galveston	2.7	9	\$1,344,926
PP180089	EPS	Adolescent Vaccination Program (AVP): Expanding a Successful Clinic-based Multicomponent HPV Vaccination Program to the San Antonio Area	Vernon, Sally W	The University of Texas Health Science Center at Houston	2.8	10	\$1,598,468

EBP: Evidence-Based Cancer Prevention Services

EPS: Expansion of Cancer Prevention Services to Rural and Medically Underserved Populations

TCL: Tobacco Control and Lung Cancer Screening

Dr. Garcia responded to Oversight Committee members' questions, explaining that the work of PP180091 is similar to Dr. Turner's STOP-HCC project. She noted that projects often target specific populations, for example the homeless population served by PP180086. When the Prevention program staff see opportunities for collaboration between projects serving the same counties, staff coordinates and encourages communication. Maps with the number of projects by county are on the CPRIT website and applicants use these to apply to cover counties not well represented in the prevention program portfolio. Dr. Garcia directed the Oversight Committee members to the "Counties of Residence Served by the 10 Recommended Prevention Projects" (page 101 of the Proposed Grants Awards book).

### Compliance Certification

Presiding Officer Montgomery reminded members that Mr. Burgess previously certified compliance of the prevention awards process, as reported by Mr. Nance.

### Conflict of Interest Notification

Presiding Officer Montgomery noted that Mr. Margo reported a conflict of interest with one of the applications under consideration, PP180091.

Presiding Officer Montgomery suggested that, unless a member objected, the Oversight Committee consider all the prevention award recommendations together in one vote except for the proposed award to PP180091, which the committee would vote on separately. No member objected.

**MOTION:**

On a motion made by Dr. Patel and seconded by Mr. Angelou, the Oversight Committee unanimously voted to approve the PIC's recommendation for the grant application PP180091.

Presiding Officer Montgomery noted for the record that Mr. Margo did not vote on this recommendation.

**MOTION:**

On a motion made by Dr. Rice and seconded by Mr. Angelou, the Oversight Committee unanimously voted to approve the PIC's recommendations for the remaining nine prevention awards.

**MOTION:**

On a motion made by Dr. Rice and seconded by Mr. Angelou, the Oversight Committee unanimously voted to approve the delegation of contract negotiation authority to CPRIT's CEO and staff and authorized the CEO to sign the contract on behalf of CPRIT.

Proposed Plan for RFAs for FY 2019 Cycle 2

Dr. Garcia presented the FY 2019 Cycle 2 RFA release schedule and timeline (page 7-2) for consideration. The proposed RFAs in the schedule include Evidence-Based Cancer Prevention Services, Expansion of Cancer Prevention Services to Rural and Medically Underserved Populations, and Tobacco Control and Lung Cancer Screening.

**MOTION:**

On a motion made by Dr. Rice and seconded by Mr. Angelou, the Oversight Committee unanimously voted to approve the Prevention Program's plan for proposed RFAs for the second cycle of FY 2019.

Communications Report

Dr. Garcia referred to her report in the meeting packet at page \*\*\*. She presented a redesigned Achievements Report, now called the Momentum Report. In addition to updated program statistics, the new document features a grant story from each program. She noted that the communication staff are working with IT on the new website roll-out tentatively scheduled for release in late November.

There were no questions for Dr. Garcia.

**Scientific Research and Prevention Program Committee Appointments – Agenda Item 11 – Tab 8**

Presiding Officer Montgomery recognized Mr. Roberts to present four appointees to CPRIT's Scientific Research Program Committees. Mr. Roberts recommended the peer review appointments for Oversight Committee approval. He noted that CPRIT provided the appointee's biographical information in the meeting packet (pages 8-3 – 8-22) and that the Nominations Subcommittee recommended approval of the appointments.

There were no questions for Mr. Roberts.

**MOTION:**

On a motion by Dr. Rice and seconded by Mr. Angelou, the Oversight Committee unanimously voted to approve the Scientific Research Program Committee appointments.

**Advisory Committee on Clinical Trials Appointments – Agenda Item 12 – Tab 9**

Mr. Roberts presented two appointees to CPRIT’s Advisory Committee on Clinical Trials. He recommended the two appointees to join the six members appointed in May 2018 by the Oversight Committee. Mr. Roberts referred members to the appointees’ biographical information CPRIT provided in the meeting packet (pages 9-3 – 9-22).

There were no questions for Mr. Roberts.

**MOTION:**

On a motion by Dr. Rice and seconded by Mr. Angelou, the Oversight Committee unanimously voted to approve the two Clinical Trials Advisory Committee appointments.

**FY 2019 Honoraria Policy - Agenda Item 13 – Tab 10**

Mr. Roberts presented the FY 2019 honoraria policy (pages \*\*\*), noting there are no substantive changes to the policy adopted for FY 2018.

There were no questions for Mr. Roberts.

**MOTION:**

On a motion made by Mr. Angelou and seconded by Dr. Rice, the Oversight Committee unanimously voted to approve the honoraria policy.

**Health & Safety Code Section 102.1062 Waivers – Agenda Item 14 – Tab 11**

Mr. Roberts presented conflict of interest waivers for Don Brandy, Dr. Becky Garcia, Dr. John Hellerstedt, Presiding Officer Will Montgomery, and a general waiver for review council members in exceptional circumstances. He referred members to pages \*\*\* in the meeting packet.

There were no questions for Mr. Roberts.

**MOTION:**

On a motion made by Dr. Rice and seconded by Mr. Margo, the Oversight Committee unanimously voted to approve the proposed Health & Safety Code Section 102.1062 waivers.

Presiding Officer Montgomery abstained from voting.

**Amendments to 25 T.A.C. Chapters 701 - 703 – Agenda Item 16 – Tab 13**

CPRIT Staff Attorney Cameron Eckel presented the final order approving amendments to Chapters 701 and 703. She reported that the Board Governance subcommittee recommended final approval for amendments to Texas Administrative Code Chapter 701 and 703, preliminarily approved by the

Oversight Committee at its May meeting. In addition, Ms. Eckel presented new proposed amendments to Chapter 703. She reported that the Board Governance subcommittee recommended that the Oversight Committee approve publication in the *Texas Register* of five proposed rule changes to Texas Administrative Code Chapter 703. She also noted that CPRIT followed the new process put in place by the Office of the Governor to submit the proposed rule changes to the Governor before publishing the proposal in the *Texas Register*.

**MOTION:**

On a motion by Dr. Rice and seconded by Mr. Margo, the Oversight Committee unanimously voted to approve the final orders adopting rules changes to the Texas Administrative Code Chapters 701 and 703.

There were no questions for Ms. Eckel.

**MOTION:**

On a motion by Dr. Rice and seconded by Mr. Margo, the Oversight Committee unanimously voted to approve the publication of the proposed changes to the Texas Administrative Code Chapter 703 in the *Texas Register*.

**Amendments to the Oversight Committee Bylaws and Code of Conduct – Agenda Item 17 – Tab 14**

CPRIT General Counsel Kristen Doyle explained a proposed revision to the Oversight Committee bylaws necessary to align the bylaws with a change made to CPRIT's statute during the 2017 legislative session. The proposed change removes a requirement that Oversight Committee members disclose and post political contributions on CPRIT's website. The legislature repealed the requirement from CPRIT's statute in 2017.

There were no questions for Ms. Doyle.

**MOTION:**

On a motion by Dr. Rice and seconded by Mr. Margo, the Oversight Committee unanimously voted to approve the change to the Oversight Committee Bylaws and Code of Conduct.

**Chief Operating Officer Report – Agenda Item 18 – Tab 15**

Ms. McConnell presented the Chief Operating Officer's report. She reported that CPRIT submitted its legislative appropriations request (LAR) on August 3. She noted that prior to the LAR's submission, the audit subcommittee confirmed it was consistent with the Oversight Committee's discussion at the May meeting. Ms. McConnell reminded members that the LAR includes two exceptional items related to general revenue and additional IT staff. She reported that the Legislative Budget Board and Governor Office have scheduled a September 4 hearing on the LAR.

Ms. McConnell discussed the FY 2019 operating budget, which CPRIT has adjusted for additional IT needs identified by the IT security audit. Ms. McConnell explained CPRIT's request to transfer funds from the Award Cancer Research Grants to Indirect Administration line.

There were no questions for Ms. McConnell.

### **Contract Approvals – Agenda Item 19 – Tab 16**

Ms. McConnell summarized the three recommended contracts presented for approval: Hahn Public Communications for strategic communications, The Perryman Group for the economic assessment for cost of cancer (contract renewal), and Weaver and Tidwell for internal audit services (contract renewal).

There were no questions for Ms. McConnell.

#### **MOTION:**

On a motion by Dr. Rice and seconded by Mr. Margo, the Oversight Committee unanimously voted to approve contract and contract renewals with Hahn Public Communications, The Perryman Group, and Weaver and Tidwell.

### **Subcommittee Business – Agenda Item 20**

Presiding Officer Montgomery announced the Board Governance Subcommittee's recommendation that Dr. Mahendra Patel fill the Board Governance chair position, which is vacant following the resignation of Amy Mitchell from the Oversight Committee.

#### **MOTION:**

On a motion by Dr. Rice and seconded by Mr. Angelou, the Oversight Committee unanimously voted to approve Dr. Patel as chair of the Board Governance Subcommittee.

### **Compliance Investigation Pursuant to Health & Safety Code 102.2631 – Agenda Item 21**

Presiding Officer Montgomery noted that the Oversight Committee would not take up Item 21.

### **Future Meeting Dates and Agenda Items – Agenda Item 23 – Tab 17**

Presiding Officer Montgomery noted that the Oversight Committee will meet November 28, 2018. He also directed members to the FY 2019 meeting dates in the meeting packet behind Tab 17.

Mr. Margo reported that he had scheduling conflicts with some of the proposed meeting dates.

### **Internal Audit – Agenda Item 15 – Tab 12**

#### **Consultation with General Counsel – Agenda Item 22**

Alyssa Martin, Internal Auditor, with Weaver and Tidwell presented her report, which included the FY 2018 Annual Internal Audit, the FY 2019 Audit Plan, the Audit Status report, the Internal Audit over Communications as well as the Follow-Up Procedures Reports over Procurement and P-Cards and Pre-Award Grant Management. She indicated that she would discuss the Follow-Up Procedures Report over IT Security with members in closed session.

Ms. Martin reported that it was a satisfactory Internal Audit Report with five findings, with only one that was high risk. Ms. Martin noted that CPRIT staff had already identified the issue and were

in the process of remedying it. She explained that she had presented all reports to the audit subcommittee and updated members on the two new audits, State Reporting and Budget and Planning, noting that the IT General Controls Audit has been deferred.

There were no questions for Ms. Martin.

Presiding Officer Montgomery announced that the Oversight Committee would go into closed session pursuant to Texas Open Meetings Act section 551.076 to discuss the security audit. He explained that to minimize the number of times the Oversight Committee would go into closed session, it would also take up Item No. 22 while in closed session to receive advice from counsel pursuant to Texas Open Meetings Act § 551.071. Presiding Officer Montgomery asked Ms. Martin and Dan Graves (Internal Auditors), Ms. McConnell, Ms. Doyle, Therry Simien, Ms. Eckel, and Mr. Roberts to join the Oversight Committee in the closed session.

Presiding Officer Montgomery convened the closed session at 11:57 a.m. and reconvened the open meeting at 12:23 p.m. He reported that the Oversight Committee would not take action on Agenda Item 22.

**MOTION:**

On a motion by Dr. Rice and seconded by Mr. Margo, the Oversight Committee unanimously voted to approve the Communications internal audit report and the three follow-up reports.

**MOTION:**

On a motion by Dr. Rice and seconded by Mr. Margo, the Oversight Committee unanimously voted to approve the FY 2019 Audit Plan.

**MOTION:**

On a motion by Dr. Rice and seconded by Mr. Margo, the Oversight Committee unanimously voted to approve the FY 2018 Internal Audit Annual Report.

Presiding Officer Montgomery reminded members that the next meeting will be November 28.


**Adjourn – Agenda Item 27**

**MOTION:**

There being no further business, the Oversight Committee unanimously approved a motion to adjourn made by Presiding Officer Montgomery and seconded Mr. Margo.

Meeting adjourned at 12:26 p.m.

Signature



Date

11/28